Clearbridge Investments Has Upped Harris Del (HRS) Holding; 7 Analysts Covering Synergy Pharmaceuticals (SGYP)

October 10, 2017 - By Ellis Scott

Clearbridge Investments Llc increased Harris Corp Del (HRS) stake by 2.03% reported in 2017Q2 SEC filing. Clearbridge Investments Llc acquired 7,328 shares as Harris Corp Del (HRS)’s stock declined 1.51%. The Clearbridge Investments Llc holds 368,772 shares with $40.23 million value, up from 361,444 last quarter. Harris Corp Del now has $16.16B valuation. The stock declined 0.11% or $0.15 reaching $135.67 on the news. About 83,927 shares traded. Harris Corporation (NYSE:HRS) has risen 39.09% since October 10, 2016 and is uptrending. It has outperformed by 22.39% the S&P500.

Among 8 analysts covering Synergy Pharmaceuticals (NASDAQ:SGYP), 7 have Buy rating, 1 Sell and 0 Hold. Therefore 88% are positive. Synergy Pharmaceuticals had 26 analyst reports since August 25, 2015 according to SRatingsIntel. The firm has “Sell” rating by Citigroup given on Thursday, April 6. The rating was reinitiated by Roth Capital on Thursday, October 29 with “”. The firm has “Buy” rating given on Monday, June 12 by H.C. Wainwright. The company was maintained on Monday, June 26 by BTIG Research. H.C. Wainwright initiated it with “Buy” rating and $20 target in Thursday, October 1 report. The firm has “Buy” rating by BTIG Research given on Tuesday, August 1. As per Thursday, August 10, the company rating was maintained by Oppenheimer. Citigroup maintained it with “Sell” rating and $2.5 target in Wednesday, September 13 report. Rodman & Renshaw maintained Synergy Pharmaceuticals Inc (NASDAQ:SGYP) on Monday, March 21 with “Buy” rating. BTIG Research initiated it with “Buy” rating and $11 target in Tuesday, August 25 report. See Synergy Pharmaceuticals Inc (NASDAQ:SGYP) latest ratings:

27/09/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $11.0 Maintain
25/09/2017 Broker: H.C. Wainwright Rating: Buy New Target: $8.0 Maintain
13/09/2017 Broker: Citigroup Rating: Sell New Target: $2.5 Maintain
08/09/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $11.0 Maintain
10/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $15.0000 Maintain
10/08/2017 Broker: Oppenheimer Rating: Buy New Target: $9.0000 Maintain
09/08/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $11.0000 Maintain
01/08/2017 Broker: BTIG Research Rating: Buy New Target: $11.0000 Maintain
31/07/2017 Broker: Canaccord Genuity Rating: Buy New Target: $13.0000
26/06/2017 Broker: BTIG Research Rating: Buy New Target: $11.0000 Maintain

About 1.75 million shares traded. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has risen 24.44% since October 10, 2016 and is uptrending. It has outperformed by 7.74% the S&P500.

Investors sentiment decreased to 1.49 in 2017 Q2. Its down 0.45, from 1.94 in 2017Q1. It worsened, as 31 investors sold Synergy Pharmaceuticals Inc shares while 22 reduced holdings. 20 funds opened positions while 59 raised stakes. 158.68 million shares or 6.77% more from 148.62 million shares in 2017Q1 were reported. Creative Planning stated it has 0% of its portfolio in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). The New York-based Metropolitan Life Insur has invested 0% in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Ingalls Snyder Ltd Llc owns 0% invested in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) for 12,952 shares. Trellus Mgmt Lc owns 2.25% invested in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) for 345,000 shares. Bank & Trust Of Montreal Can has invested 0% in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Legal And General Group Incorporated Plc accumulated 56,358 shares. State Of Wisconsin Inv Board stated it has 0% of its portfolio in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). The Massachusetts-based State Street has invested 0.01% in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). D E Shaw Co Inc stated it has 46,659 shares or 0% of all its holdings. Great Point Ptnrs Ltd has invested 5.76% of its portfolio in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Hightower Advisors Lc holds 804,506 shares. Zurcher Kantonalbank (Zurich Cantonalbank) reported 3,778 shares stake. Moreover, Manufacturers Life Ins The has 0% invested in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) for 174,647 shares. Bankshares Of Ny Mellon has 0% invested in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Parametric Portfolio Limited Liability has invested 0% in Synergy Pharmaceuticals Inc (NASDAQ:SGYP).

Since May 26, 2017, it had 2 insider buys, and 0 insider sales for $43,302 activity. BRANCACCIO JOHN P bought $23,335 worth of stock or 6,500 shares. Another trade for 5,680 shares valued at $19,967 was bought by JACOB GARY S.

Synergy Pharmaceuticals Inc. is a biopharmaceutical firm focused on the development and commercialization of gastrointestinal therapies. The company has market cap of $753.60 million. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. It currently has negative earnings. The Firm is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Since May 31, 2017, it had 0 insider purchases, and 1 sale for $3.76 million activity. On Wednesday, May 31 DUFFY ROBERT L sold $3.76 million worth of Harris Corporation (NYSE:HRS) or 33,600 shares.

Clearbridge Investments Llc decreased Anadarko Pete Corp stake by 36,731 shares to 1.08 million valued at $44.45 million in 2017Q2. It also reduced Delphi Automotive Plc (NYSE:DLPH) stake by 48,422 shares and now owns 595,217 shares. C H Robinson Worldwide Inc (NASDAQ:CHRW) was reduced too.